EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Inhaled tranexamic acid as a treatment option in nonmassive hemoptysis: a randomized controlled trial

Eman A.A. Ali, Mohamed M. El-Gamal, Manal M.R. Algharbawy

The Egyptian Journal of Chest Diseases and Tuberculosis · 2026-04 · 75 (2) · 247-254

DOI: 10.4103/ecdt.ecdt_62_25 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Egyptian Journal of Chest Diseases and Tuberculosis, online erschienen am 08.04.2026. Verfasst von Eman A.A. Ali und 2 weiteren Autor:innen. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hemoptysis is a potentially life-threatening condition with variable etiology and severity. Tranexamic acid (TXA), an antifibrinolytic agent, has demonstrated efficacy in bleeding control. Nebulized TXA offers targeted pulmonary delivery with reduced systemic exposure, but clinical evidence remains limited.

Objectives

To evaluate the efficacy and safety of nebulized TXA in patients with nonmassive hemoptysis. Patients and methods This randomized, double-blind, placebo-controlled trial was conducted at Mansoura University Hospitals. Adult patients with nonmassive hemoptysis were randomized to receive either nebulized TXA (500 mg in 5 ml normal saline, three times daily) or nebulized placebo (normal saline). The primary outcome was hemoptysis cessation within 5 days. Secondary outcomes included length of hospital stay, recurrence rate within 3 months, and need for interventional procedures. Data were analysed using appropriate statistical tests, including logistic and linear regression to adjust for confounders.

Results

A total of 114 patients were enrolled (study group: n =36; control group: n =78). Both groups were comparable in baseline demographic and clinical characteristics. The mean time to hemoptysis cessation was significantly shorter in the TXA group compared with the control group (2.1±0.95 vs. 6.36±3.06 days; P

Zitieren

APA

Ali, E. A., El-Gamal, M. M., & Algharbawy, M. M. (2026). Inhaled tranexamic acid as a treatment option in nonmassive hemoptysis: a randomized controlled trial. The Egyptian Journal of Chest Diseases and Tuberculosis, 75(2), 247-254. https://doi.org/10.4103/ecdt.ecdt_62_25

Vancouver

Ali EA, El-Gamal MM, Algharbawy MM. Inhaled tranexamic acid as a treatment option in nonmassive hemoptysis: a randomized controlled trial. The Egyptian Journal of Chest Diseases and Tuberculosis. 2026;75(2):247-254. doi:10.4103/ecdt.ecdt_62_25

BibTeX
@article{Ali2026,
  author = {Ali, Eman A.A. and El-Gamal, Mohamed M. and Algharbawy, Manal M.R.},
  title = {Inhaled tranexamic acid as a treatment option in nonmassive hemoptysis: a randomized controlled trial},
  journal = {The Egyptian Journal of Chest Diseases and Tuberculosis},
  year = {2026},
  volume = {75},
  number = {2},
  pages = {247--254},
  doi = {10.4103/ecdt.ecdt_62_25}
}
Kostenlos starten →